Skip to main content


  • Poster presentation
  • Open Access

HIV-patients discrimination according to phenotype and functional assay of T-cells subsets

  • 1Email author,
  • 1,
  • 1 and
  • 1
Retrovirology20107 (Suppl 1) :P26

  • Published:


  • Viral Load
  • Discriminant Function Analysis
  • Healthy Blood Donor
  • Cluster Category
  • Cluster Definition


To distinguish HIV-1 patients with clinical diversity by using a simplified model of T-cell interactions


During 28 months, 1074 blood samples from 200 HIV-1 patients and 418 blood samples from healthy blood donors were prospectively collected. T lymphocyte subsets and activation markers expression (CD4, CD69, CD25, CD8, CD28, HLA-DR) were determined initially and after PHA stimulation in whole blood cultures.


Two step Cluster Analysis followed by a discriminant function analysis of the lymphocyte activation assay from the first blood sample, allowed the separation of HIV-1 patients in two groups: Cluster1 (67%) and Cluster2 (33%). Clusters definition relied on the level of three T-cells subsets: a) stimulated CD4+CD69+CD25high, b) unstimulated CD4+CD69+CD25+ and c) unstimulated CD4+CD25high. PHA stimulated CD4+CD69+ CD25high subset level alone allowed to classify correctly patients with 92% sensitivity and 87% specificity. Cluster-2 expressed more CD69 and HLA-DR activation markers on CD4 and CD8 lymphocytes, less CD8+CD28+ and responded less to mitogen even if viral load undetectable. Cluster-2 presented poorly clinical profile in terms of previous AIDS events, current CD4+ count, viral load, length of treatment. Over the time most patients (64%) were keeping their cluster category.


We propose an algorithm to identify a subset of HIV patients with an over-determined immunodeficiency status characterized by a lower ability to reverse inappropriate activation of CD4 and CD8 T-lymphocytes leading probably to earlier exhaustion of their immunological resources. This subgroup of patients could display a worst clinical evolution, lower control capacity of viral load, even under antiretroviral therapy-mediated viral suppression.

Authors’ Affiliations

CHU-Brugmann, Bruxelles, Belgium


© Guillaume et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.